Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | CALML3 | P27482 | 1/20 | 0.38 |
| ▸ | SDHA | P31040 | 1/20 | 0.38 |
| ▸ | FADS1 | O60427 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5382916 | 0.85 | MAOA (0.41) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5375213 | 0.84 | MAOA (0.43) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5370421 | 0.84 | MAOA (0.40) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL4880673 | 0.83 | MAOA (0.51) | MAOAGRM2MAOBLMNAPTGS1 | |
| SCHEMBL5375020 | 0.80 | GRM2 (0.41) | MAOASIGMAR1GRM2MAOBLMNA | |
| SCHEMBL5374404 | 0.80 | GRM5 (0.38) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL4880677 | 0.78 | MAOA (0.41) | MAOASIGMAR1GRM2MAOBLMNA | |
| SCHEMBL5383280 | 0.74 | MAOA (0.51) | MAOASIGMAR1GRM2MAOBLMNA | |
| SCHEMBL14197115 | 0.73 | F10 (0.46) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL14224728 | 0.73 | MAOA (0.54) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279494-B2 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | PFIZER INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20050192325-A1 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | RENSLO ADAM (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192325-A1 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | OXA1L, CYP51A1, CYP2C19 | MAOA 1957/4885SIGMAR1 450/4885GRM2 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.